Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 0
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its flagship product is Sepranolone, which is used for the treatment of menstrual migraine and Tourette syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, reasonably
Data is available to registered users only
Buy
Sell